🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Recruitingn/aAges 18 Years - 80 YearsAllUniversity of Roma La Sapienza
NCT04464122 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group); * Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group). Exclusion Criteria: * Severe chronic kidney disease (stage 4-5); * Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease; * Other non-neuroendocrine malignancies.
💊

What it tests

  • Somatostatin analog; chemotherapy
📍

Where

1 site
Andrea M Isidori
Rome, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy